Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35565, first published .
Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Journals

  1. Sunavala-Dossabhoy G, Petti S. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review. Oral Oncology 2023;136:106280 View
  2. Piciu D, Bran S, Moldovan M, Varvara S, Piciu A, Cuc S, Moisescu-Goia C, Barbus E, Mester A, Onisor F. Radioiodine-131 Therapy Used for Differentiated Thyroid Cancer Can Impair Titanium Dental Implants: An In Vitro Analysis. Cancers 2023;15(9):2558 View
  3. Baudin C, Bressand A, Buffet C, Menegaux F, Soret M, Lê A, Cardon T, Broggio D, Bassinet C, Huet C, Armengol G, Richardson D, Leenhardt L, Bernier M, Lussey-Lepoutre C. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid® 2023 View
  4. Villela R, Correa R. Lacrimal and Salivary Gland Dysfunction Following Radioiodine Therapy for Thyroid Cancer. Clinical Thyroidology® 2023;35(9):384 View
  5. Legrand A, Bernier M, Bressand A, Buffet C, Mandin C, Menegaux F, Soret M, Broggio D, Bassinet C, Huet C, Leenhardt L, Lussey-Lepoutre C, Baudin C. Health-related quality of life and radioiodine therapy in thyroid cancer patients: a before-and-after study. Quality of Life Research 2024 View